This trial is a single arm, two cohorts, phase Ib/II study. All patients are stage IIIB/C or
IV NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Cohort 1 includes
treatment naïve patients with advanced NSCLC. Cohort 2 includes patients with metastatic or
recurrent NSCLC after progression on treatment with PD-1/PD-L1. The primary end point are
objective response rate per RECIST1.1 and safety. Secondary end points are progression-free
survival and overall survival.